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INTRODUCTION 
    Metabolic syndrome (MS) represents a cluster of metabolic disorders 
that increase the risk of type 2 diabetes (DM2) and cardiovascular 
diseases [1]. The relevancy of MS is shown by its high prevalence and 
also by the fact that it plays a key role in the pathogenesis of many 
disorders, especially DM2, obesity, hypertension, cardiovascular diseases 
and others [2]. MS is characterized by tissue resistance to insulin action, 
hyperinsulinemia, impaired glucose tolerance and dyslipidemia, essential 
hypertension, abdominal (visceral) obesity, hyperuricaemia, coagulation 
disturbances and fibrinolysis, and endothelial dysfunction [3].  
     Insulin resistance (IR) is a basic metabolic abnormality of MS. It is a 
common pathological state in which target cells fail to respond to 
ordinary levels of circulating insulin [4]. It results in an inability of 
insulin to provide normal glucose and lipid homeostasis. IR increases the 
demand for insulin secretion by pancreatic β-cells and leads to 
compensatory hyperinsulinemia. IR involves metabolic disturbances in 
skeletal muscle, liver and adipose tissue, resulting in reduced insulin-
mediated glucose utilization.  
     The causes of the rise and development of IR, according to current 
ideas are multifactorial. The aetiology of IR includes genetic factors, 
increasing age as well as environmental factors related to lifestyle such 
as food intake associated with obesity and reduced physical activity. The 
causes of IR are particularly disorders in the insulin signaling cascade, 
the defect may occur at any stage in the cascade of events beginning with 
the binding of insulin to insulin receptors, tyrosine kinase activation, the 
cascade of phosphorylation and dephosphorylation reactions and 
terminating with the activation of effector systems that are responsible 
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for mediating the biological effects of insulin. Protein kinase C (PKC) is 
an important component of the insulin signaling cascade and numerous 
recent studies have demonstrated that PKC plays a pivotal role in the 
development of IR. 
     Great attention is also paid to the role of adipose tissue, which does 
not function merely as a reservoir of energy in the form of triglycerides, 
but produces a range of mediators (adipokines) that are involved in the 
inflammatory process and that may also interact with components of the 
insulin signaling cascade, thereby contributing to the development of IR. 
Among adipokines, TNFα and resistin are particularly involved in the 
development of IR, while in contrast adiponectin increases insulin 
sensitivity [5].  
     The increased availability and utilization of free fatty acids (FFA) 
play a critical role in the development of IR [2, 6]. In IR, visceral adipose 
tissue is resistant to the antilipolytic effect of insulin and consequently 
releases excessive amounts of FFA. Elevated FFA impair insulin 
sensitivity in insulin responsive tissues and negatively affect insulin 
transduction through a well known cascade of events (activation of 
cellular kinases). FFA also induce IR in skeletal muscles [7].  
     PKC is a serine/threonine kinase, which is involved in the 
pathogenesis of IR and its related complications [8, 9]. The PKC family 
comprises 12 isoforms that have been subdivided into three groups based 
on structural similarities and mechanisms of activation: the conventional, 
novel and atypical PKCs [10]. Individual PKC isoforms differ in their 
functions, co-factor requirements, substrates, and different tissue and 
intracellular localization. PKCs play a dual role in insulin signaling. 
They are involved in the transduction of specific insulin signals but also 
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contribute to the generation of IR. PKC ζ and λ are the most important 
isoforms in mediating the effect of insulin on glucose transporter 
translocation and glucose uptake [11]. PKC ε and PKC θ play a key role 
in skeletal muscle IR, their selective activation was demonstrated in a 
number of dietary-induced IR models [8, 9, 12]. These isoforms act as 
inhibitors of insulin signal transduction and interfere with insulin 
signaling, leading to reduced insulin signal transmission and ultimately 
to reduced skeletal muscle insulin sensitivity. Insulin sensitivity of the 
muscle is closely associated with the triglyceride content. Elevated 
concentrations of diacylglycerol (DAG) (an intermediate of triglyceride 
and phospholipid synthesis) are considered to be a link between PKC 
activation, lipid metabolism disorders and increased IR of skeletal 
muscle.  
 
AIMS OF THE THESIS 
Studying the pathogenesis of IR 
- studying the pathogenesis of IR in relation to the cellular localization 
and the relative amounts of PKC ε and PKC θ in the skeletal muscle of 
HHTg rats  
- developing a method for measuring the activity of glycogen synthase 
(GS) and analysing its role in the pathogenesis of IR  
- monitoring the parameters of IR in relation to PKC ε and PKC θ after 
nutritionally induced obesity in HHTg rats and during the ontogenesis of 
HHTg rats 
Studying the role of resistin in the pathogenesis of IR  
- monitoring the effect of increased resistin expression in the adipose 
tissue of SHR rats on lipid and carbohydrate metabolism in relation to 
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the cellular localization and relative amounts of PKC ε and PKC θ in 
skeletal muscle  
Possibilities for pharmacological treatment of IR 
- studying the metabolic effects of long-term pioglitazone treatment of 
SHR-4 rats on ectopic lipid accumulation, skeletal muscle and adipose 
tissue resistance and on the relative amounts of PKC ε and PKC θ in 
skeletal muscle  
 
MATERIAL AND METHODS 
Experimental models  
Strain of hereditary hypertriglyceridemic rats (HHTg) - a suitable non-
obese model for studying the pathogenesis of IR, exhibits almost all the 
symptoms of MS (dyslipidemia, hyperinsulinemia, impaired glucose 
tolerance, hypertension). Hypertriglyceridemia is genetically fixed and 
potentiated by a sucrose-rich diet (SRD).  
Strain of Wistar rats - Wistar rats were used as controls to HHTg rats 
Strain of spontaneously hypertensive rats (SHR-4) – the congenic SHR-4 
strain is genetically identical to the SHR strain except for the differential 
segment of chromosome 4, including FAT/Cd36. In addition to 
genetically fixed hypertension, this strain exhibits other metabolic 
abnormalities (dyslipidemia, hyperinsulinemia, glucose intolerance), 
which can be potentiated by SRD or a fructose-rich diet (FRD).  
Transgenic strain of SHR rats expressing mouse resistin – a new 
transgenic strain of SHR rats expressing a nonsecreted form of mouse 
resistin under the control of the aP2 promoter predominantly in adipose 
tissue [13]. This strain allows the study the potential role of resistin in the 
pathogenesis of IR in SHR rats.  
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Methods 
Biochemical analysis – determination of serum triglycerides, FFA, 
glucose, cholesterol, insulin, adiponectin and tissue concentrations of 
proteins and triglycerides using commercially available analytical kits  
Analysis to assess insulin resistance in peripheral tissues and glucose 
tolerance - in vitro incorporation of 14C-U-glucose into skeletal 
muscle/diaphragm glycogen or epididymal fat pad lipids in the basal 
state or after insulin stimulation and the oral glucose tolerance test 
(OGTT)  
PKC analysis - homogenization and fractionation of skeletal muscle to 
obtain cytosolic and membrane fractions, protein quantification of the 
fractions, electrophoresis and Western blotting, immunodetection, 
enhanced chemiluminescence, computer processing  
Activity of GS - activity assayed by measuring the incorporation of 14C-
glucose from uridine 5'-diphosphate glucose into glycogen  
 
RESULTS AND DISCUSSION 
 
Effect of nutritionally induced obesity on PKC and insulin resistance 
in HHTg rats  
     Experiments were performed in 18-months-old control Wistar rats, 
HHTg and obese HHTg rats. The obesity of HHTg rats was induced by 
diet: HHTg rats were fed a SRD for seven months and became obese, 
while control and HHTg rats were fed a standard laboratory diet. Obesity 
is one of the factors that contribute to the development of IR, and it is 
associated with a higher prevalence of DM2 and cardiovascular 
complications. In numerous studies performed in both humans and 
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animals, it has been shown that a decrease or increase of body weight is 
closely correlated with increasing or decreasing insulin sensitivity, 
respectively [14; 15; 16]. 
     The serum concentrations of triglycerides and FFA were significantly 
higher in HHTg rats when compared with control rats. In addition, HHTg 
rats exhibited an impaired sensitivity of the peripheral tissues to insulin 
action. Another characteristic of these rats is ectopic storage of 
triglycerides in the liver and skeletal muscle, which negatively affects 
the insulin sensitivity of these tissues.   
     Feeding HHTg rats a SRD compared with HHTg rats fed a standard 
diet resulted in increased body weight, increased weight of the 
epididymal fat pad, and increased serum concentrations of glucose, 
triglycerides and FFA. This model of nutritionally induced obesity 
corresponds fairly well to the situation in humans, because the increased 
intake of sucrose over the past few decades is considered to be one of the 
reasons for the significant increase in obesity and its related 
complications. Increased levels of plasma triglycerides, glucose and also 
insulin were found in obese insulin-resistant Zucker rats [17]. A common 
finding in obese subjects is elevated serum FFA concentrations caused 
by their increased release from excessive fatty tissue [18]. FFA affect 
metabolic functions in many tissues and contribute to the reduced insulin 
sensitivity of peripheral tissues. Obesity is also associated with ectopic 
lipid storage [19]. Nutritionally induced obesity in HHTg rats was 
accompanied by a significant accumulation of triglycerides in the liver.  
     In the membrane fraction of skeletal muscle of HHTg rats, we found a 
lower relative amount of PKC ε when compared to controls. The amount 
of PKC ε in HHTg rats was not affected by obesity. In HHTg rats, we 
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found a lower amount of PKC θ in the cytosol and a higher relative 
amount of PKC θ in the membrane fraction when compared to controls. 
A decrease of PKC θ in the cytosol and an increase of membrane-
associated PKC θ are considered to be an indicator of PKC translocation 
and activation [8; 20]. Nutritionally induced obesity in HHTg rats tended 
to further increase PKC θ activation. Decreased skeletal muscle insulin 
sensitivity in HHTg rats was accompanied by PKC θ activation. 
     In most studies on IR and the possible role of PKC ε in its 
pathogenesis, increased PKC ε activity has been found. However, in our 
study we found lower activation of PKC ε in HHTg rats compared to 
controls. A similar finding was described in further research in obese 
Zucker rats. Cooper et al. found reduced PKC activity and smaller 
quantities of PKC ε in skeletal muscle compared to Zucker lean control 
animals [21]. There could be various explanations for these different 
findings concerning PKC ε. The increased activation of PKC ε may 
increase the translocation, protein turnover but also the degradation of 
PKC. A genetic mutation causing the altered function or inactivation of 
PKC may also play a role [21].  
     The finding of increased PKC θ activation in insulin-resistant HHTg 
rats is consistent with the literature. In our study, we measured the 
accumulation of triglycerides in skeletal muscle, which contributes to 
PKC activation. Triglyceride metabolism is associated with the 
production of biologically active metabolites such as DAG, which is the 
PKC activator [19]. Activated PKC θ phosphorylates serin hydroxyl 
residues of IRS1 (insulin receptor substrate) and IRS2. It reduces IRS1 
and IRS2 tyrosine phosphorylation, resulting in the reduced activity of 
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PI3K (fosfatidylinositol-3-kinase) and leads to reduced glucose transport 
[22]. These effects of PKC θ decreases insulin signal transduction and 
contribute to IR.  
     Our findings show that HHTg rats are a suitable model for the study 
of IR. Nutritionally induced obesity in HHTg rats further enhanced a 
number of abnormalities of lipid and carbohydrate metabolism associated 
with IR. The results suggest that PKC θ could play an important role in 
the pathogenesis of IR in skeletal muscle. 
 
Glycogen synthase activity and insulin resistance  
     GS is one of the effector molecules responsible for mediating the 
biological effects of insulin. GS activity is reduced in the skeletal 
muscles of patients with DM2 [23]. In our study, we measured GS 
activity in the skeletal muscle of HHTg rats and control Wistar rats. At 
the age of four months, all animals were fed a SRD for two weeks. 
Feeding a SRD to HHTg rats resulted in an exaggeration of metabolic 
abnormalities. After overnight fasting (16 hours), half of the animals in 
each group received an oral single dose of glucose (3 g/kg b. wt.) and 
were killed 30 minutes later. This experimental design allowed us to test 
the response of the organism to the rise of endogenous insulinemia, 
which reflects its actual metabolic state. The aim of our study was to 
identify the mechanism of impaired glucose utilization in muscle tissue 
during the initial phase of OGTT.  
     In the fasting state, GS activity did not differ between control and 
HHTg rats. After a single dose of glucose, the enzyme activity 
significantly increased in controls, while in HHTg rats it remained 
unchanged compared with the fasting state. This finding was supported 
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by the finding of reduced levels of glycogen in the skeletal muscle of 
HHTg rats [24]. Several studies have shown decreased insulin-stimulated 
glucose uptake in DM2, which was associated with impaired GS activity 
and glycogen synthesis [25; 26].  
     We have demonstrated that impaired glucose utilization in the 
peripheral tissues of HHTg rats is accompanied by the reduced activity of 
GS in skeletal muscle. Metabolic maladaptation to the transition from 
fasting to the fed state may be one of the mechanisms underlying the 
impaired glucose utilization in the non-obese model of IR. Decreased GS 
activity and glucose utilization in peripheral tissues suggest a possible 
defect in insulin signal transduction in the cells. A defect in one or more 
steps in this signaling cascade, where one of the important effector 
molecules is also GS, plays a role in the development of IR.  
 
Influence of aging on PKC and insulin resistance 
          It has been long known that IR progressively increases with age in 
both humans and rats [27; 28], but the mechanisms implicated in the 
worsening of IR and other accompanying symptoms with increasing age, 
are not fully understood. It is assumed that these disorders are associated 
with changes in body composition, i.e. an increased proportion of body 
fat and obesity, rather than with aging itself [29; 30].  
     Experiments were conducted in HHTg rats and control Wistar rats 
aged 4- and 18- months. The animals were fed a standard laboratory diet, 
then received a SRD for two weeks before the end of the study.  
     The relative weight of the epididymal fat pads, which is considered 
as an indicator of visceral obesity, remained unaltered in HHTg rats with 
age. As this parameter highly correlates with body fat percent [31], it can 
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be claimed that the cause of IR deterioration with age was not obesity. 
This claim is opposed to the theory proposing that the cause of the age-
related deterioration of IR is a higher amount of body fat due to obesity. 
Here a link may exist that reconciles both contradictory claims, i.e. that 
age-related deteriorating IR is caused by obesity and our finding that it is 
independent of obesity. It has been speculated that increased serum FFA 
levels may be the primary defect resulting in decreased glucose 
utilization in tissues, and, subsequently, in hyperinsulinemia [32]. 
Hyperinsulinemia may be the compensatory mechanism of IR in the 
peripheral tissue preventing an increase in gluconeogenesis in the liver 
and, hence, hyperglycemia [33]. In our study, HHTg rats showed 
increased serum FFA levels that tended to rise with age and increase 
following SRD.  
     Serum triglyceride levels were higher in HHTg rats fed a standart diet 
compared with controls and tended to rise with age. A SRD for two 
weeks raised triglyceridemia irrespective of age, by 80 % in the HHTg 
strain, and by 35 % in the control group. In the HHTg rat strain, 
hypertriglyceridemia is genetically fixed and, as indicated by the study 
results, it continues to increase with age.  
    Another finding in HHTg rats was reduction in insulin-stimulated 
glucose utilization in adipose tissue and the diaphragm. Defects of 
glucose utilization were more apparent in 18-months-old animals 
compared with younger ones. At the age of 18 months, the impaired 
glucose tolerance of the HHTg strain became even more pronounced and 
also became partly manifest in the control group, although, at that age, 
the sensitivity of the peripheral tissue to insulin action in the control 
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group was only slightly greater than in the completely resistant tissues of 
the HHTg group.  
     Decreased cellular insulin signaling is a potential mechanism 
responsible for the defects in insulin action characteristic of old age. 
PKC may negatively affect insulin signal transmission. We found no 
differences in the relative amount of PKC ε protein between young and 
old HHTg and control rats in the cytosol and membrane fraction. These 
findings are consistent with the results of Qu et al, who, also found no 
changes in PKC activity or PKC ε and PKC θ subcellular distribution in 
skeletal muscle between young and old nondiabetic rats [34]. Unlike the 
results of the above-mentioned study, we observed differences in PKC θ 
levels, but at an advanced age. In HHTg rats, we found significantly 
larger amounts of PKC θ in the cytosol and membrane fraction. IR in 18-
months-old HHTg rats was accompanied by an overall increase in the 
relative amount of protein PKC θ in skeletal muscle. Individual PKC 
isoforms may differ in their expression in muscle and may have different 
functions. PKC θ is the major PKC isoform expressed in skeletal muscle, 
and most studies point to a relationship between PKC θ and IR [35; 36]. 
The increased amount of PKC θ in old HHTg rats may be related to 
elevated concentrations of triglycerides in skeletal muscle. Triglycerides 
are indicators of the presence of other lipid intermediates, such as DAG, 
and LCACoA (long-chain acyl-CoA), which are PKC activators [37]. An 
accumulation of triglycerides was found in the skeletal muscle of HHTg 
rats in the previous study [38]. 
          The results indicate that the age-related increase in IR and the 
deterioration of some parameters of carbohydrate and lipid metabolism 
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are associated with an overall increase in the relative amount of PKC θ in 
the skeletal muscle of HHTg rats. These findings suggest the possible 
involvement of PKC θ in IR of skeletal muscle disorders.  
 
Effect of resistin overexpression in adipose tissue on PKC and 
insulin resistance  
     Resistin is a protein produced by adipose tissue and which has been 
suggested to represent a molecular link between obesity, IR and DM2 
[39]. This hypothesis is supported by studies in which the serum 
concentrations of resistin were increased in rodent models of obesity and 
DM2 [39] and by the observation that acute in vivo administration of 
large amounts of recombinant resistin is associated with hepatic IR and 
impaired glucose tolerance [40].   
     Experiments were performed in one-year-old SHR rats with the 
resistin transgene. This strain expresses mouse resistin in adipose tissue 
that is not detectable in the circulation, thus providing a unique 
opportunity to study the autocrine effects of resistin in adipose tissue 
[13]. The control group comprised age-matched genetically identical rats 
without the transgene. All animals were fed a FRD two weeks before the 
end of the study.  
     The transgenic rats exhibited increased serum concentrations of 
insulin and triglycerides and markedly impaired glucose tolerance. These 
findings are consistent with the results of previous studies in other 
transgenic models, such as Wistar rats with chronic resistin over-
expression. These rats showed glucose intolerance during a glucose 
tolerance test, hyperinsulinemia and elevated serum levels of 
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triglycerides [41]. Resistin expression in SHR rats did not affect skeletal 
muscle insulin sensitivity and was not accompanied by an accumulation 
of triglycerides in skeletal muscle or the liver. In addition, it did not lead 
to elevated serum concentrations of FFA.  
     The used animal model expresses mouse resistin in adipose tissue 
and showed a near total resistance of the adipose tissue to insulin action. 
This finding suggests an autocrine effect of resistin in adipose tissue, and 
it appears that resistin may negatively affect insulin signaling. A number 
of in vivo studies have shown that resistin negatively influences insulin 
signal transduction not only in adipose tissue, but also in the liver and 
skeletal muscle [42; 43].  
     Chronic transgenic expression of resistin did not affect the relative 
amount of PKC ε in the studied cellular fractions, but a significant 
increase in PKC θ levels was found in both the cytosolic and membrane 
fractions. Increased skeletal muscle PKC θ activity was found in 
transgenic mice expressing human resistin which were fed a high-fat diet 
[44]. Increased amounts of skeletal muscle triglycerides and DAGs were 
found in these animals. The reason for the increased relative amount of 
PKC θ found in our study is not clear because in SHR transgenic rats we 
did not detect ectopic storage of triglycerides in the skeletal muscle or 
increased FFA levels in the circulation. FFA in the circulation can 
directly stimulate production of DAG in muscle and activate PKC θ [18].  
     The  results of  our  study support  the hypothesis of  a role of resistin  
in the pathogenesis of IR. They suggest its autocrine effects in adipose 
tissue that may be, together with increasing age, considered to be a 
predisposition to diabetes. The role of PKC in the mechanisms 
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underlying the deterioration of metabolic abnormalities that accompany 
increased resistin expression in adipose tissue has not yet been clarified.  
 
Effect of long-term pioglitazone treatment on PKC and insulin 
resistance  
     Thiazolidinediones (TZDs) such as pioglitazone are insulin 
sensitizing drugs used for the treatment of DM2. TZDs improve 
glycemic control by reducing insulin resistance in the target tissues. They 
are PPARγ agonists (peroxisome proliferator-activated receptor γ), which 
regulate the transcription of genes sensitive to insulin and are involved in 
regulating glucose and lipid metabolism in adipose and muscle tissue. 
Their mechanism of action is not yet fully understood [45]. 
     In these study, we tested a hypothesis that TZDs ameliorate IR in 
muscle tissue by suppressing muscle lipid storage and the activation of 
novel PKC isozymes. Specifically, we analyzed the long-term metabolic 
effects of pioglitazone in an animal model of MS, SHR-4 rats. SHR-4 
rats in an experimental group were fed a SRD supplemented with 
pioglitazone (300 mg/ kg diet) from the age of 4 to 8 months. SHR-4 
controls were fed a SRD without pioglitazone for the same time. The 
SHR-4 congenic strain with the wild type FAT/Cd36 gene was selected 
instead of the SHR that harbors a deletion variant because FAT/Cd36 is a 
target gene involved in the insulin sensitizing actions of pioglitazone 
[46].  
     Pioglitazone-treated SHR-4 rats showed decreased serum 
triglycerides and FFA, which are likely metabolic consequences of 
PPARγ activation in adipose tissue. The activation of these receptors by 
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TZDs reduces the rate of FFA release and amplifies insulin-stimulated 
glucose transport.  
     Long-term pioglitazone treatment of SHR-4 rats increased adipose 
tissue insulin sensitivity, which was accompanied by increased protein 
content in adipose tissue. This finding suggests a remodeling of adipose 
tissue, involving a multiplication of small, metabolically active, insulin- 
sensitive fat cells [47]. Our findings are consistent with the hypothesis 
that TZDs influence adipose tissue metabolism. They can influence the 
differentiation, size and total number of adipocytes within a particular fat 
depot as well as regulating insulin signaling, glucose and lipid 
metabolism in mature adipocytes [47]. In addition, pioglitazone-treated 
rats exhibited significantly decreased levels of serum insulin while 
hyperinsulinemia was observed in SHR-4 control rats fed a SRD. 
Decreased levels of serum insulin, triglycerides and FFA suggest the 
amelioration of systemic IR and dyslipidemia.  
     TZD treatment is usually associated with significantly decreased 
intramyocellular lipid levels [48; 49]. According to a widely accepted 
hypothesis, the lipid reducing effects of TZDs in skeletal muscles are 
considered as possible insulin sensitizing mechanisms acting through 
reducing the activity of novel PKC isoforms in particular, thereby 
ameliorating insulin signaling. Surprisingly, in the current study, we 
observed that long-term pioglitazone treatment was associated with 
increased triglyceride levels in the gastrocnemius muscle, with activation 
of the PKC ε and PKC θ isoforms, and with amelioration of insulin- 
stimulated glycogenesis. These findings are similar to the results of 
Lessard et al. [50], who found ameliorated glucose tolerance in obese 
Zucker rats treated with rosiglitazone despite the fact that these rats 
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exhibited significantly increased intramyocellular triglycerides in the 
soleus muscle when compared to glucose intolerant controls. The reason 
for these discrepant results regarding the effects of TZD on skeletal 
muscle lipid accumulation is unclear. It has been suggested that the effect 
of TZD on lipid storage might depend on the predominant type of muscle 
fibers. For instance, most of studies showing reduced skeletal muscle 
lipid content after TZD treatment analyzed muscles with a large 
percentage of type II fibers (glycolytic fibers), while Lessard et al. [50] 
analyzed the soleus muscle containing predominantly type I fibers 
(oxidative fibers). The gastrocnemius muscle used in the current study, 
contains both type I and type II fibers, suggesting that the differential 
effects of TZD on lipid storage in skeletal muscle might not depend on 
the muscle type. It is also possible that increased triglyceride levels in the 
gastrocnemius muscle might be explained by the reduced activity of 
hormone sensitive lipase (HSL), which is a lipase for DAGs [51]. 
Downregulation of HSL could be associated with increased DAG, which 
in turn might affect the activation of PKC ε and PKC θ.  
     Serum concentrations of adiponectin in pioglitazone-treated rats were 
significantly higher compared to controls. The positive effect of TZDs  
on IR is related to the stimulation of adiponectin production.  
Adiponectin can play an important role in the mechanism responsible for 
enhancing the insulin sensitivity of peripheral tissues [52]. 
     In conclusion, the results of the current study demonstrate that long-
term pioglitazone treatment can ameliorate IR in muscle tissue as well as 
many other parameters of lipid and carbohydrate metabolism. Increased 
skeletal muscle triglyceride accumulation after pioglitazone treatment 
was associated with the activation of PKC ε and PKC θ. The favourable 
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effects of TZDs are probably due to the remodeling of adipose tissue and 
increased adiponectin secretion. 
 
SUMMARY 
Studying the pathogenesis of insulin resistance and the role of PKC 
in insulin resistance 
• In  HHTg  rats, elevated  serum  triglycerides and  FFA were associated   
with the ectopic accumulation of triglycerides in tissues and reduced 
insulin sensitivity of peripheral tissues. Impaired glucose utilization in 
the peripheral tissues was associated with the reduced activity of GS in 
skeletal muscle. Decreased GS activity and glucose utilization in 
peripheral tissues indicate a possible defect in insulin signal 
transduction. In line with this, our results show that skeletal muscle IR 
was associated with the increased activation and translocation of PKC θ. 
 
• Nutritionally induced obesity of HHTg rats resulted, in many cases, in 
the further deterioration of metabolic abnormalities associated with 
IR. We found that PKC θ, in particular, could contribute to the metabolic 
abnormalities associated with IR and obesity. 
 
• The age-related increase in IR and deterioration of some parametres of 
carbohydrate and lipid metabolism, were not associated, in HHTg rats, 
with obesity but with increased serum levels of triglycerides and FFA. 
 
• The age-related worsening of IR in HHTg rats was accompanied by 
increased relative amounts of PKC θ in skeletal muscle. These findings 
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suggesting the possible involvement of PKC θ in skeletal muscle IR 
disorders.  
 
Studying the potential role of resistin in the pathogenesis of insulin 
resistance 
• The chronic transgenic expression of resistin in adipose tissue in SHR 
rats was associated with disorders of lipid and carbohydrate metabolism, 
the resistance of adipose tissue to insulin action and a significant increase 
in the relative amount of PKC θ in skeletal muscle. 
 
• The results support the hypothesis of a role of resistin in the 
mechanisms underlying IR, suggesting its autocrine effects on adipose 
tissue. Whether PKC may play a role in the deterioration of metabolic 
abnormalities, which is accompanied by the increased expression of 
resistin in adipose tissue, was not completely resolved. 
 
Effects of pharmacological intervention in insulin resistance 
• Long-term pioglitazone treatment positively influenced the metabolic 
abnormalities associated with IR. It decreased the serum concentrations 
of triglycerides and FFA, increased the insulin sensitivity of adipose and 
muscle tissue, increased the serum levels of adiponectin and avoided the 
development of hyperinsulinemia. By contrast, pioglitazone increased 
skeletal muscle triglyceride accumulation and activated PKC ε and    
PKC θ. 
 
• The beneficial effects of TZDs can be explained by the remodeling of 
adipose tissue and increased adiponectin secretion. 
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LIST OF ABBREVIATIONS 
 
DAG     diacylglycerol 
DM2     type 2 diabetes mellitus 
FFA      free fatty acids 
FRD      fructose rich diet 
GS        glycogen synthase 
HHTg   hereditary hypertriglyceridemic rat 
HSL      hormone sensitive lipase 
IR          insulin resistance 
IRS        insulin receptor substrate 
MS         metabolic syndrome 
OGTT    oral glucose tolerance test 
PKC       protein kinase C 
PPARγ   peroxisome proliferator-activated receptor γ 
SHR       spontaneously hypertensive rat 
SRD       sucrose rich diet 
TZDs     thiazolidinediones 
